RLAY (Relay Therapeutics) Market Value to Book Value Ratio

Official company branding of Relay Therapeutics (RLAY)

The price action for Relay Therapeutics (RLAY) shown on this chart reflects the quotes of an asset whose technological moat is based on unique protein motion analysis software and AI. Cash flow is generated through payments from pharma behemoths and the future commercialization of drugs. The current figure is 4.45. Business efficiency is bolstered by alliances with industry leaders that integrate the Dynamo digital platform with biochemistry.

Relay Corp (RLAY): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for Relay Therapeutics Inc (RLAY)

- price and consensus price forecast:
Stock Quotes Relay Therapeutics|RLAY - Average Forecast Price
- market capitalization data:
Market Value Relay Pharma|RLAY - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Relay Therapeutics|RLAY - Accounting Capitalization|Market Capitalization to Book Value Ratio relaytx.com|RLAY - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Relay Therapeutics|RLAY - Long-Term Liabilities to Capital|Short-Term Debt to Equity Relay Pharma|RLAY - Company Debts|Debt to Book Capitalization Ratio Relay Pharma
Fundamental valuation:Relay Therapeutics
Brand item of Relay Pharma

For Relay Therapeutics (RLAY), whose valuation is driven by breakthroughs in AI oncology and regulatory approvals rather than consumer cycles, cost of capital analysis is critical. This metric measures the market premium over net assets, showing how much investors are willing to pay over one dollar of book value, which allows the premium of market valuation over book value to signal asset overbought conditions in a timely manner.

Competitor analysis

Market Cap to Net Assets Ratio GMAB|EXEL (exelixis.com) - Market-to-Book Ratio|Market Value to Book Value Ratio NUVL (Nuvalent)|Market-to-Book Ratio KYMR|Market Value to Book Value Ratio IDEAYA Bio IDYA|Capitalization to Book Value Ratio Enliven Corp (ELVN)|ORIC Pharmaceuticals - Market Capitalization to Book Value Ratio|nurixtx.com - Market Cap to Net Assets Ratio|TYRA (Tyra Biosciences) - Market Value to Book Value Ratio|VSTM: Market-to-Book Ratio|Monte Rosa Tx (GLUE) - Market Value to Book Value Ratio|CGEM (Cullinan Corp) - Market Value to Book Value Ratio|Market Value to Book Value Ratio IMRX (Immuneering Corporation)|Market-to-Book Ratio c4therapeutics.com|BDTX: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Repare Therapeutics, Inc. RPTX|PMVP: Market Cap to Net Assets Ratio|KPTI - Market-to-Book Ratio|Market Cap to Net Assets Ratio Propanc Biopharma, Inc. (PPCB)|cyclacel.com (BGMS) - Market Value to Book Value|AADI - Market Cap to Net Assets Ratio|Aileron Therapeutics, Inc. (ALRN) - Market Cap to Book Value Multiple|BPMC (Blueprint Medicines Corp.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GLYC|SpringWorks Therapeutics (SWTX) - Market Value to Book Value Ratio